Page 160 - Genentech News Today

For a much-anticipated town hall, BLACK ENTERPRISE has tapped in the incomparable Ed Gordon, CEO of Ed Gordon Media, to moderate "The Future Of Work."

Operator: Welcome to the Lineage Cell Therapeutics First Quarter 2023 Conference Call. At this time, all participants are in a listen-only mode.

Mosquito Crystallography are automated systems for protein crystallization screening that utilize crystallography-based structural biology, allowing rapid, reliable, and reproducible crystallization screen transfers.

Monica Bertagnolli, Biden's nominee for Director of the National Institutes of Health (NIH), got nearly $300 million in grants from pharmaceutical companies.

/PRNewswire/ -- The "Bi-Specific MAbS Global Market Report 2023" report has been added to ResearchAndMarkets.coms offering. This report provides strategists,...

In patients with systemic lupus erythematous, CAR T-cell therapy appears to be a feasible and effective method of achieving durable remission, according to a speaker at the Biologic Therapies Summit.“Lupus patients often need quite substantial amounts of glucocorticoids to stay in remission, and that is a huge problem,” Georg Schett, MD, of Friedrich-Alexander University, in Germany,

Get a glimpse of the global clinical trial landscape of antibody drug conjugates (ADCs) and their trends in the Asia Pacific.


This trial is significant because pancreatic cancer is one of the most difficult solid tumour cancers to treat and the progress in treatments has been slow, says Dr Shailesh Shrikhande, who heads India's highest volume centre for pancreatic cancer surgery at Mumbai’s Tata Memorial Hospital

The frontline combination of ribociclib and letrozole significantly prolonged overall survival over letrozole alone in a subset of patients with hormone receptor–positive, HER2-negative advanced breast cancer who had de novo metastatic disease or late recurrence from neoadjuvant therapy, according to data from an exploratory analysis of the phase 3 MONALEESA-2 trial.

Let's review three pharma companies based outside the U.S. that promise reasonable valuations and solid dividend yields....JNJ